A phase II proof-of-concept study of PUR-1800 in patients with chronic obstructive pulmonary disease (COPD)
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2017
At a glance
- Drugs PUR 1800 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Proof of concept; Therapeutic Use
- 30 Oct 2017 According to a Pulmatrix media release, this study is expected to begin in 2H 2018.
- 08 Aug 2017 New trial record
- 04 Aug 2017 According to a Pulmatrix media release, the company expects to complete this study in the fourth quarter of 2018.